nmendation	Pag No
a commonly used term in the title or	1
mative and balanced summary of what	2
and rationale for the investigation being	3
any prespecified hypotheses	3
gn early in the paper	4
l relevant dates, including periods of	4
and data collection	
the sources and methods of selection of	4
ures, predictors, potential confounders,	4
tic criteria, if applicable	
sources of data and details of methods	4
cribe comparability of assessment	
group	
ential sources of bias	4
ived at	4
were handled in the analyses. If	5
gs were chosen and why	
, including those used to control for	5
examine subgroups and interactions	5
addressed	5
al methods taking account of sampling	N/A
es	N/A
	1
at each stage of study—eg numbers	5
eligibility, confirmed eligible, included	
, and analysed	
ion at each stage	14
1	N/A
rticipants (eg demographic, clinical,	5
res and potential confounders	
with missing data for each variable of	5-7
s or summary measures	5
if applicable, confounder-adjusted	8-9
5% confidence interval). Make clear for and why they were included	
i i	or summary measures f applicable, confounder-adjusted % confidence interval). Make clear

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

		(b) Report category boundaries when continuous variables were	5
		categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute	N/A
		risk for a meaningful time period	
Other analyses	17	Report other analyses done-eg analyses of subgroups and interactions,	N/A
		and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	9
Limitations	19	Discuss limitations of the study, taking into account sources of potential	11
		bias or imprecision. Discuss both direction and magnitude of any potential	
		bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	9-11
		limitations, multiplicity of analyses, results from similar studies, and other	
		relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	11
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study	1
		and, if applicable, for the original study on which the present article is	
		based	

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.